Zachary D. Wallen

This study identifies dysbiotic gut microbiome features in Parkinson's disease, links them to genetic variants, and proposes microbiome-based biomarkers for targeted treatment.

This study shows that alpha-synuclein overexpression in mice alters gut microbiome composition with age, suggesting a potential link between PD pathology and microbiome dysbiosis.

The paper develops microbiome-based biomarkers to identify suitable patients for microbiome-based therapies in Parkinson's disease, showing that not all patients have dysbiotic microbiomes and that dysbiotic microbiomes vary in features.

This study investigates the gut microbiome's role in Parkinson's disease using metagenomics, finding widespread dysbiosis and associations with disease mechanisms.

This study compares 16 differential abundance methods on two Parkinson disease gut microbiome datasets, finding varied results and highlighting the need for replication across methods and datasets.

The paper shows that genetic variants at the alpha-synuclein locus influence gut microbiome dysbiosis in Parkinson's disease.

The paper identifies 31 host genetic loci influencing gut microbiome composition through GWAS and suggests causal effects in inflammatory diseases.

This study identifies three clusters of gut microbiota associated with Parkinson's disease, including overabundance of opportunistic pathogens.